BioPharmSignal logoBioPharmSignal

Biotech News

Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline

Carisma Therapeutics, Inc. (CARM)Carisma Therapeutics, Inc.Company update

Resources realigned to focus primarily on in vivo macrophage engineering platform for fibrosis, oncology and autoimmune disease therapies Development of CT-0525 to be discontinued; workforce reduced by 34% PHILADELPHIA , Dec. 9, 2024 /PRNewswire/ -- Carisma Therapeutics Inc.

Related news

FATEFate Therapeutics2026-09-16 11:00 EST

Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026

FATEFate Therapeutics2026-09-09 11:00 EST

Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting

KURAKura Oncology2026-09-09 11:00 EST

Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes

ELVNEnliven Therapeutics2026-09-03 20:05 EST

Enliven Therapeutics to Present at Upcoming Investor Conferences

NRIXNurix Therapeutics2026-09-01 12:00 EST

Nurix Therapeutics to Participate in Upcoming September Investor Conferences

ELVNEnliven Therapeutics2026-08-31 22:05 EST

Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

NRIXNurix Therapeutics2026-08-20 11:00 EST

Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer

KYMRKymera2026-07-27 20:01 EST

Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer

CMPXCompass Therapeutics2026-07-17 14:42 EST

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026

SNDXSyndax Pharmaceuticals2026-07-14 12:00 EST

Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event

View all latest news

Carisma Therapeutics, Inc.

Carisma Therapeutics is a cell-therapy company focused on engineered macrophages and cancer immunotherapy. Its story centers on using a novel immune-cell approach to attack tumors.

Recent company news

CARMCarisma Therapeutics, Inc.2025-12-05 16:16 EST

Carisma Announces Delisting from Nasdaq and SEC Deregistration

CARMCarisma Therapeutics, Inc.2025-03-31 20:30 EST

Carisma Therapeutics Provides Corporate Updates

CARMCarisma Therapeutics, Inc.2025-02-19 12:30 EST

Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

CARMCarisma Therapeutics, Inc.2025-02-05 12:30 EST

Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference

CARMCarisma Therapeutics, Inc.2024-12-09 13:30 EST

Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline

Stock data

Close
0.00 USD
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States